Atara Biotherapeutics News

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and

BusinesswireJun 7 16:01 ET

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and

BusinesswireJun 5 16:01 ET

12 Health Care Stocks Moving In Friday's After-Market Session

GainersLiquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday's after-market session. The market value of their outstanding shares is at $1.1 billion. Adagene (NASDAQ:ADAG) shares moved upward

BenzingaMay 31 16:32 ET

Atara Biotherapeutics Hold Rating Based on Promising Preclinical Data and Awaited Clinical Trials

TipRanksMay 30 22:16 ET

Stifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)

TipRanksMay 30 07:57 ET

Express News | Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases

ReutersMay 29 16:03 ET

Express News | Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic Cd19-Targeted Car T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the Isct 2024 Annual Meeting

ReutersMay 29 16:01 ET

H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating

H.C. Wainwright analyst Robert Burns maintains $Atara Biotherapeutics(ATRA.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 24.0% and a total average return of -22

moomoo NewsMay 23 05:34 ET

Express News | Adiumentum Capital Fund I LP Reports 6.7% Stake in Atara Biotherapeutics as of May 15- SEC Filing

ReutersMay 22 18:27 ET

Express News | Adiumentum Capital Fund I LP: To Engage in Talks With Atara Biotherapeutics to Discuss Business, Financial Condition, Strategic Plans, Governance

ReutersMay 22 18:26 ET

Express News | Adiumentum Capital Fund I LP Says Acquired Beneficial Ownership of Atara Biotherapeutics Common Stock Shares in Belief Stock Was Undervalued

ReutersMay 22 18:22 ET

This Insider Has Just Sold Shares In Atara Biotherapeutics

We note that the Atara Biotherapeutics, Inc. (NASDAQ:ATRA) President, Pascal Touchon, recently sold US$50k worth of stock for US$0.62 per share. It might not be a huge sale, but it did reduce their

Simply Wall StMay 22 08:36 ET

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Neutral.

BenzingaMay 22 07:07 ET

Atara Biotherapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 — HC Wainwright & Co. Reiterates → Neutral 04/01/2024 249.7% Stifel $4.8 → $2.3 Maintains Hold

BenzingaMay 22 07:05 ET

Atara Biotherapeutics: A Balanced Hold Amidst FDA Approval Prospects and Valuation Uncertainties

TipRanksMay 22 06:26 ET

Les Laboratoires Pierre Fabre Annoncent La Soumission Par Atara Biotherapeutics D'une Demande De Licence Biologique De Tabelecleucel (Tab-cel) Pour Le Traitement De La Maladie Lymphoproliférative Post-transplantation Et Positive Au Virus...

Les Laboratoires Pierre Fabre Annoncent La Soumission Par Atara Biotherapeutics D'une Demande De Licence Biologique De Tabelecleucel (Tab-cel) Pour Le Traitement De La Maladie Lymphoproliférative Pos

PR NewswireMay 22 04:43 ET

Pierre Fabre Laboratories Announces the Submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S FDA

Pierre Fabre Laboratories today announce the submission by Atara Biotherapeutics (ATARA), a leader in T-cell immunotherapies, of Tabelecleucel...

PR NewswireMay 21 12:59 ET

Sector Update: Health Care Stocks Ease Monday Afternoon

Health care stocks were lower Monday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose

MT NewswiresMay 20 13:59 ET

Atara Biotherapeutics Files Biologics License Application for Tabelecleucel With FDA; Shares Rise

Atara Biotherapeutics (ATRA) said Monday it has filed a biologics license application with the US Food and Drug Administration for tabelecleucel, or tab-cel, to treat patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease.

MT NewswiresMay 20 11:57 ET

Express News | Atara Eligible for Additional $60M Upon FDA Approval

ReutersMay 20 09:25 ET